Published in Circulation on January 30, 2015
Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction. Circulation (2016) 0.96
Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance. PLoS One (2015) 0.88
The role of titin and extracellular matrix remodelling in heart failure with preserved ejection fraction. Neth Heart J (2016) 0.86
Dasatinib Attenuates Pressure Overload Induced Cardiac Fibrosis in a Murine Transverse Aortic Constriction Model. PLoS One (2015) 0.84
Phosphorylating Titin's Cardiac N2B Element by ERK2 or CaMKIIδ Lowers the Single Molecule and Cardiac Muscle Force. Biophys J (2015) 0.83
Biomarkers in heart failure with preserved ejection fraction. Neth Heart J (2016) 0.83
Myocardial hypertrophy and its role in heart failure with preserved ejection fraction. J Appl Physiol (1985) (2015) 0.83
Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail (2016) 0.81
Cardiosphere-derived cells reverse heart failure with preserved ejection fraction (HFpEF) in rats by decreasing fibrosis and inflammation. JACC Basic Transl Sci (2016) 0.80
Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction. J Am Heart Assoc (2016) 0.79
Emerging Novel Therapies for Heart Failure. Clin Med Insights Cardiol (2015) 0.78
Right Ventricular Myocardial Stiffness in Experimental Pulmonary Arterial Hypertension: Relative Contribution of Fibrosis and Myofibril Stiffness. Circ Heart Fail (2016) 0.77
Could Modification of Titin Contribute to an Answer for Heart Failure With Preserved Ejection Fraction? Circulation (2016) 0.76
Mechanical Regulation of Cardiac Aging in Model Systems. Circ Res (2016) 0.76
Exploring Guidelines for Classification of Major Heart Failure Subtypes by Using Machine Learning. Clin Med Insights Cardiol (2015) 0.76
Pharmacological Strategies to Retard Cardiovascular Aging. Circ Res (2016) 0.76
Cardiovascular consequences of metabolic syndrome. Transl Res (2017) 0.75
Obesity alters molecular and functional cardiac responses to ischemia/reperfusion and glucagon-like peptide-1 receptor agonism. Basic Res Cardiol (2016) 0.75
Two Kinases to Soften the Heart. Biophys J (2016) 0.75
Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. J Card Fail (2015) 0.75
Diastolic Left Ventricular Function in Relation to Urinary and Serum Collagen Biomarkers in a General Population. PLoS One (2016) 0.75
Heart rate-induced modifications of concentric left ventricular hypertrophy: exploration of a novel therapeutic concept. Am J Physiol Heart Circ Physiol (2016) 0.75
Therapeutic potential of targeting microRNAs to regulate cardiac fibrosis: miR-433 a new fibrotic player. Ann Transl Med (2016) 0.75
Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin". Circulation (2015) 0.75
Early-stage heart failure with preserved ejection fraction in the pig: a cardiovascular magnetic resonance study. J Cardiovasc Magn Reson (2016) 0.75
Mechanisms underlying the cardiac antifibrotic effects of losartan metabolites. Sci Rep (2017) 0.75
Heart failure with preserved ejection fraction and skeletal muscle physiology. Heart Fail Rev (2017) 0.75
Reversal of maladaptive fibrosis and compromised ventricular function in the pressure overloaded heart by a caveolin-1 surrogate peptide. Lab Invest (2017) 0.75
Alternative Splicing of Titin Restores Diastolic Function in an HFpEF-Like Genetic Murine Model (TtnΔIAjxn). Circ Res (2016) 0.75
Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction. Circ Heart Fail (2016) 0.75
Pericardiectomy to Treat Heart Failure With Preserved Ejection Fraction: Unrestrained Enthusiasm? Circ Heart Fail (2017) 0.75
The Effects of Guizhi Gancao Decoction on Pressure Overload-Induced Heart Failure and Posttranslational Modifications of Tubulin in Mice. Evid Based Complement Alternat Med (2017) 0.75
Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction. Curr Hypertens Rep (2017) 0.75
Tampering with springs: phosphorylation of titin affecting the mechanical function of cardiomyocytes. Biophys Rev (2017) 0.75
Myocardial wall stiffening in a mouse model of persistent truncus arteriosus. PLoS One (2017) 0.75
Human heart failure with preserved ejection versus feline cardiomyopathy: what can we learn from both veterinary and human medicine? Heart Fail Rev (2017) 0.75
PM2.5 exposure in utero contributes to neonatal cardiac dysfunction in mice. Environ Pollut (2017) 0.75
INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. Circ Heart Fail (2017) 0.75
Targeting Obesity and Diabetes to Treat Heart Failure with Preserved Ejection Fraction. Front Endocrinol (Lausanne) (2017) 0.75
Relationship of long-term prognosis to MMP and TIMP polymorphisms in patients after ST elevation myocardial infarction. J Appl Genet (2017) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med (2006) 10.58
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation (2002) 8.49
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Diastolic heart failure--abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med (2004) 8.12
The progression from hypertension to congestive heart failure. JAMA (1996) 7.56
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail (2010) 6.37
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol (2013) 5.04
PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat Med (2004) 4.50
The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J (2006) 4.10
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation (2009) 3.55
Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation (2011) 3.48
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial. Circulation (2006) 3.40
The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res (2004) 3.30
Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation (2004) 3.29
Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation (2007) 3.12
Myocardial structure and function differ in systolic and diastolic heart failure. Circulation (2006) 3.11
Titin isoform switch in ischemic human heart disease. Circulation (2002) 3.05
Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA (2011) 2.86
Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ Res (2008) 2.73
Changes in titin and collagen underlie diastolic stiffness diversity of cardiac muscle. J Mol Cell Cardiol (2000) 2.54
Vertical agarose gel electrophoresis and electroblotting of high-molecular-weight proteins. Electrophoresis (2003) 2.46
Cardiomyocyte stiffness in diastolic heart failure. Circulation (2005) 2.43
Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol (2010) 2.38
Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J (2013) 2.32
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol (2009) 2.20
Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation (2012) 2.14
Passive stiffness changes caused by upregulation of compliant titin isoforms in human dilated cardiomyopathy hearts. Circ Res (2004) 2.09
Protein kinase A phosphorylates titin's cardiac-specific N2B domain and reduces passive tension in rat cardiac myocytes. Circ Res (2002) 2.07
Heart failure with a normal ejection fraction: is measurement of diastolic function necessary to make the diagnosis of diastolic heart failure? Circulation (2001) 2.05
Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res (2009) 1.99
Shortening of the elastic tandem immunoglobulin segment of titin leads to diastolic dysfunction. Circulation (2013) 1.83
The influence of basic residues on the substrate specificity of protein kinase C. J Biol Chem (1987) 1.80
Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation (2008) 1.65
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail (2012) 1.62
Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J Am Coll Cardiol (2011) 1.41
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
Microplate reader-based quantitation of collagens. Anal Biochem (1992) 1.34
Gigantic business: titin properties and function through thick and thin. Circ Res (2014) 1.33
Functional effects of protein kinase C-mediated myofilament phosphorylation in human myocardium. Cardiovasc Res (2005) 1.30
Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail (2010) 1.29
Titin is a major human disease gene. Circulation (2013) 1.29
Hypothyroidism leads to increased collagen-based stiffness and re-expression of large cardiac titin isoforms with high compliance. J Mol Cell Cardiol (2006) 1.28
Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur J Heart Fail (2008) 1.28
Titin: physiological function and role in cardiomyopathy and failure. Heart Fail Rev (2005) 1.22
Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness. Circulation (2011) 1.22
Crucial role for Ca2(+)/calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res (2013) 1.20
Myofilament dysfunction in cardiac disease from mice to men. J Muscle Res Cell Motil (2009) 1.19
Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. J Cardiovasc Transl Res (2013) 1.15
Contribution of titin and extracellular matrix to passive pressure and measurement of sarcomere length in the mouse left ventricle. J Mol Cell Cardiol (2011) 1.15
Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model. Circ Heart Fail (2013) 1.14
Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol (2014) 1.12
Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res (2012) 1.11
Excision of titin's cardiac PEVK spring element abolishes PKCalpha-induced increases in myocardial stiffness. J Mol Cell Cardiol (2009) 1.08
Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo. Circulation (2011) 1.07
Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol (2012) 1.06
The multifunctional Ca(2+)/calmodulin-dependent protein kinase II delta (CaMKIIδ) phosphorylates cardiac titin's spring elements. J Mol Cell Cardiol (2012) 1.06
Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep (2009) 1.02
Sensitive spectrophotometric method for the quantitative estimation of collagen. Anal Biochem (1985) 1.02
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res (2013) 0.97
Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. -Comparison between preserved and reduced ejection fraction heart failure.-. Circ J (2011) 0.90
Time course of right ventricular pressure-overload induced myocardial fibrosis: relationship to changes in fibroblast postsynthetic procollagen processing. Am J Physiol Heart Circ Physiol (2012) 0.89
Myocardial titin and collagen in cardiac diastolic dysfunction: partners in crime. Circulation (2013) 0.87
Myosin cross-bridge dynamics in patients with hypertension and concentric left ventricular remodeling. Circ Heart Fail (2012) 0.86
Transcriptional and posttranslational modifications of titin: implications for diastole. Circ Res (2009) 0.85
Heart failure with preserved ejection fraction. Pflugers Arch (2014) 0.82
Extensible behavior of titin in the miniswine left ventricle. Circulation (2010) 0.81
Combined immunoelectron microscopic and computer-assisted image analyses to detect advanced glycation end-products in human myocardium. Histochem Cell Biol (2010) 0.77